Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-007
CTR20255034Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of calderasib, pembrolizumab, tergase, pemetrexed, carboplatin in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Feb 2026; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20255034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255034.